Posted by Michael Wonder on 19 Oct 2025
Artiva Biotherapeutics announces refractory rheumatoid arthritis as lead indication
16 October 2025 - Artiva Biotherapeutics announced today that the US FDA has granted fast track designation to AlloNK (also known as AB-101) for the treatment of refractory rheumatoid arthritis in combination with rituximab.
AlloNK is believed to represent the first drug candidate in the deep B-Cell depleting therapeutic category to receive this designation in refractory rheumatoid arthritis.
